Nuveen Asset Management, LLC Ikena Oncology, Inc. Transaction History

Nuveen Asset Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$1.33 - $4.4 $4,387 - $14,515	3,299 Added 9.99%	36,322 $71,000
Q2 2023 Aug 14, 2023	BUY	$3.5 - $7.31 $115,580 - $241,398	33,023 New	33,023 $216,000
Q2 2022 Aug 15, 2022	SELL	$3.23 - $7.4 $239,368 - $548,399	-74,108 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$5.61 - $13.85 $7,377 - $18,212	1,315 Added 1.81%	74,108 $540,000
Q4 2021 Feb 14, 2022	BUY	$10.52 - $16.96 $417,738 - $673,464	39,709 Added 120.02%	72,793 $997,000
Q3 2021 Nov 12, 2021	BUY	$9.82 - $15.23 $59,204 - $91,821	6,029 Added 22.28%	33,084 $429,000
Q2 2021 Aug 16, 2021	BUY	$13.27 - $26.0 $359,019 - $703,430	27,055 New	27,055 $379,000

30.6M

Ticker IKNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,257,500
Market Cap $56.2M
Description
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. I...

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nuveen Asset Management, LLC with notifications on news.